Vitamin d and malaria drug join forces against pancreatic cancer
NCT ID NCT04524702
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested whether adding paricalcitol (a vitamin D drug) and hydroxychloroquine (an autophagy inhibitor) to standard chemotherapy could help shrink tumors in 10 people with advanced or metastatic pancreatic cancer. The goal was to see if the combination improved tumor response rates. Results are not yet widely available, but this small study may guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
paricalcitol (a form of vitamin D) and hydroxychloroquine (an autophagy inhibitor) added to gemcitabine and nab-paclitaxel chemotherapy
What this could lead to
If it works, this combination could improve tumor response in advanced pancreatic cancer, potentially leading to a new treatment option.
What could go wrong
This is a small, early-phase trial with only 10 participants, so results may not apply broadly. The added drugs could increase side effects without clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory Saint Joseph's Hosptial
Atlanta, Georgia, 30342, United States
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States